Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

May 18, 2022

Irish bioscience firm pledges to open U.S. HQ in New Haven

By Liese Klein, New Haven Biz

Nuritas, a bioscience company based in Ireland, announced on Tuesday it planned to open a new U.S. headquarters in New Haven. 

Nuritas uses artificial intelligence to develop drugs using plant-based bioactive peptides, the company said in a statement. It currently has its U.S. base in Cambridge, Mass.

Founder and CEO Nora Khaldi will discuss Nuritas’s expansion at the Yale Innovation Summit, scheduled to begin Tuesday afternoon.

Nuritas plans to hire 10 to 15 people for science, engineering and research roles in the New Haven area over the next 12 months, according to a spokesperson. The company plans to set up both laboratory and manufacturing facilities in the state. 

“We are incredibly excited to expand our U.S. team with the kind of commercial and scientific talent and resources available in Connecticut and nearby Boston and New York,” Khaldi said. 

The U.S. expansion comes in the wake of a $45 million Series B capital raise and anticipates “the launch of key products in its pipeline,” according to Nuritas. Chicago-based Cleveland Avenue led the funding round.

PHOTO | COURTESY NURITAS

Nuritas’s genomics platform, called Nπϕ (Nuritas Peptide Finder), identifies short strings of amino acids in plants and “natural food sources” and predicts how they could impact human health, molecular pathways or receptors. The peptides are then validated in the lab, clinically tested, then scaled and patented with the goal of going to market with products.

The company was founded in 2014 and launched a set of supplements using its proprietary peptides in 2020. Using peptides found in the pea, PeptiYouth claims to slow down cellular aging, PeptiStrong claims to build muscle and PeptiForce claims to optimize glucose metabolism, according to the Nuritas website. 

Yale Innovation Summit keynote speaker Indra Nooyi, former CEO of PepsiCo, is on the advisory board of Nuritas. Early investors in the company include Bono and The Edge of Irish rock band U2. 

The company is working with AdvanceCT and Yale Ventures on its move to New Haven. An exact location has yet to be determined.

AdvanceCT CEO Peter Denious said, “We are incredibly excited to work with Dr. Khaldi and the team at Nuritas to bring their level of innovation to our area and grow their North American presence with key U.S. partners.”

Contact Liese Klein at lklein@newhavenbiz.com.

Sign up for Enews

Most Recent

Most Recent

0 Comments

Order a PDF